Therapie des „high-output failure“ bei Sepsis

  • H. Forst
  • T. Bein
  • J. Briegel
  • H. Hellinger
  • M. Haller
  • M. Stieglitz
  • F.-P. Lenhart
Part of the Anaesthesiologie und Intensivmedizin / Anaesthesiology and Intensive Care Medicine book series (A+I, volume 222)


Charakteristische hämodynamische Befunde bei Sepsis sind der verminderte periphere Gefäßwiderstand, ein hohes Herzzeitvolumen und meist ein erhöhter Widerstand in der pulmonalen Strombahn [31, 79]. Die Tatsache, daß nach Volumenzufuhr Herzzeitvolumen und Schlagvolumen bei den meisten Patienten im septischen Schock normal oder sogar gegenüber der Norm erhöht sind, hat dazu geführt, daß oft die Einschränkung der myokardialen Pumpfunktion unterschätzt oder als ein Spätsymptom der hypodynamen Schockform angesehen wird. Ein erhöhtes Herzzeitvolumen allein bedeutet aber bei extrem erniedrigtem peripherem Gefäßwiderstand noch nicht, daß auch die Myokardfunktion normal oder dieses Herzzeitvolumen den Bedürfnissen des Organismus adäquat ist [59].


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Abel FL (1989) Myocardial function in sepsis and endotoxin shock. Am J Physiol 257: R1265 - R1281PubMedGoogle Scholar
  2. 2.
    Armistead CW Jr, Vincent J-L, Preiser J-C, De Backer D, Le Minh T (1989) Hypertonic saline solution-hetastarch for fluid resuscitation in experimental septic shock. Anesth Analg 69: 714–720PubMedCrossRefGoogle Scholar
  3. 3.
    Ball HA, Cook JA, Halushka PV (1986) Role of thromboxane, prostaglandins and leukotrienes in endotoxic and septic shock. Intensive Care Med 12: 116–126PubMedCrossRefGoogle Scholar
  4. 4.
    Barzilay E, Kessler D, Berlot G, Gullo A, Geber D, Ben Zeev I (1989) Use of extracorporeal supportive techniques as additional treatment for septic-induced multiple organ failure patients. Crit Care Med 17: 634–637PubMedCrossRefGoogle Scholar
  5. 5.
    Baue AE, Guenther B, Hartl W, Ackenheil M, Heberer G (1984) Altered hormonal activity in severely ill patients after injury or sepsis. Arch Surg 119: 1125–1132PubMedGoogle Scholar
  6. 6.
    Baumgartner JD, Glauser MP, McCutchan JA et al. (1985) Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet 11: 59–63CrossRefGoogle Scholar
  7. 7.
    Besse JC, Bass AD (1966) Potentiation by hydrocortisone of responses to catecholamines in vascular smooth muscle. J Pharmacol Exp Ther 154: 224–238PubMedGoogle Scholar
  8. 8.
    Bihari D, Smithies M, Gimson A, Tinker J (1987) The effects of vasodilation with prostacyclin on oxygen transport and uptake in critically ill patients. N Engl J Med 317: 397–402PubMedCrossRefGoogle Scholar
  9. 9.
    Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA (1987) Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome. Chest 92: 1032–1036PubMedCrossRefGoogle Scholar
  10. 10.
    Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA, and the methylprednisolone severe sepsis study group (1987) A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 317: 653–658PubMedCrossRefGoogle Scholar
  11. 11.
    Böhm M, Gierschik P, Jakobs KH, Kemkes B, Schnabel P, Erdmann E (1989) Mechanismus der verminderten Katecholaminwirkung im Schock and bei Herzinsuffizienz. Intensivmedizin 26: 55–59Google Scholar
  12. 12.
    Briegel J, Hellinger H, Forst H, Haller M, Bein T, Peter K (im Druck) Hydrocortison and Katecholamin-Bedarf während Sepsis. AnaesthesistGoogle Scholar
  13. 13.
    Catalano RD, Parameswaran V, Ramachandran J, Trunkey DD (1984) Mechanisms of adrenocorticol depression during Escherichia coli shock. Arch Surg 119: 145–150PubMedGoogle Scholar
  14. 14.
    Cunnion RE, Parrillo JE (1989) Myocardial dysfunction in sepsis. Recent insights. Chest 95: 941–945PubMedCrossRefGoogle Scholar
  15. 15.
    Cunnion RE, Schaer GL, Parker MM, Natanson C, Parrillo JE (1986) The coronary circulation in human septic shock. Circulation 73: 637–644PubMedCrossRefGoogle Scholar
  16. 16.
    De Groote MA, Martin MA, Densen P, Pfaller MA, Wenzel RP (1989) Plasma tumor necrosis factor levels in patients with presumed sepsis. Results in those treated with antilipid A antibody vs. placebo. JAMA 262: 249–251PubMedCrossRefGoogle Scholar
  17. 17.
    De la Cal MA, Miravalles E, Pascual T, Esteban A, Ruiz-Santana S (1984) Dose-related hemodynamic and renal effects of dopamine in septic shock. Crit Care Med 12: 22–25PubMedCrossRefGoogle Scholar
  18. 18.
    Demeules JA (1984) A physiologic explanation for cardiac deterioration in septic shock. J Surg Res 36: 553–562PubMedCrossRefGoogle Scholar
  19. 19.
    Dennhardt R, Gramm H-J, Meinhold K, Voigt K (1989) Patterns of endocrine secretion durch sepsis. Prog Clin Biol Res 308: 751–756PubMedGoogle Scholar
  20. 20.
    Dhainaut J-F, Huyghebaert M-F, Monsallier JF et al (1987) Coronary hemodynamics and myocardial metobolism of lactate, free fatty acids, glucose, and ketones in patients with septic shock. Circulation 75: 533–541PubMedCrossRefGoogle Scholar
  21. 21.
    Dhainaut JF, Schlemmer B, Monsallier JF, Huyghebaert MF, Brunet F, Villemant D, Carli A (1984) Oxygen consumption during septic shock. Effects of inotropic drugs. Arch Int Physiol Biochim 92: 57–64CrossRefGoogle Scholar
  22. 22.
    Dinarello CA, Mier JW (1987) Lymphokines. N Engl J Med 317: 940–945CrossRefGoogle Scholar
  23. 23.
    Dunn DL, Priest BP, Condie RM (1988) Protective capacity of polyclonal and monoclonal antibodies directed against endotoxin during experimental sepsis. Arch Surg 123: 1389–1393PubMedGoogle Scholar
  24. 24.
    Ellrodt AG, Riedinger MS, Kimichi A, Berman DS, Maddahi J, Swan HJ, Murata GH (1985) Left ventricular performance in septic shock: reversible segmental and global abnormalities. Am Heart J 110: 402–409PubMedCrossRefGoogle Scholar
  25. 25.
    Emerson TE Jr (1989) Unique features of albumin: a brief review. Crit Care Med 17: 690–694PubMedCrossRefGoogle Scholar
  26. 26.
    Erdmann E, Reuschel-Janetschek E (1989) Hämodynamik in der Sepsis and im septischen Schock. Intensivmedizin 26: 16–21Google Scholar
  27. 27.
    Fleck A, Hawker F, Wallace PI, Raines G, Trotter J, Ledingham IM, Calman KC (1985) Increased vascular permeability: a major cause of hypalbuminemia in disease and injury. Lancet I: 781–783Google Scholar
  28. 28.
    Forst H, Haller M, Adler M (1989) Effects of transfusion on systemic oxygen uptake. In: Vincent JL (ed) Update 1989. Springer, Berlin Heidelberg New York Tokyo (Update in intensive care and emergency medicine, vol 8, pp 215–223 )Google Scholar
  29. 29.
    Goldblum SE, Sun WL (1990) Tumor necrosis factor-a augments pulmonary arterial transendothelial albumin flux in vitro. Am J Physiol 258: L57 - L67PubMedGoogle Scholar
  30. 30.
    Greenburg AG (1990) To transfuse or not to transfuse–That is the question. Crit Care Med 18: 1045–1045PubMedCrossRefGoogle Scholar
  31. 31.
    Groeneveld ABJ, Bronsveld W, Thijs LG (1986) Hemodynamic determinants of mortality in human septic shock. Surgery 99: 140–153PubMedGoogle Scholar
  32. 32.
    Groeneveld ABJ, Thijs LG (1987) Systemic microvascular permeability in septic shock. In: Vincent JL, Thijs LG (eds) Septic shock. Springer, Berlin Heidelberg New York Tokyo (Update in intensive care and emergency medicine, vol 4, pp 43–50 )Google Scholar
  33. 33.
    Haglund U (1987) Myocardial depressant substances in septic shock. In: Vincent JL, Thijs LG (ds) Septic shock. Springer, Berlin Heidelberg New York Tokyo (Update in intensive care and emergency medicine, vol 4, pp 129–138)Google Scholar
  34. 34.
    Hanasawa K, Tani T, Kodama M (1989) New approach to endotoxic and septic shock by means of polymyxin B immobilized fiber. Surg Gynecol Obstet 168: 323–331PubMedGoogle Scholar
  35. 35.
    Harada H, Ishizaka A, Yonemaru M et al (1989) The effects of aminophylline and pentoxifylline on multiple organ damage after Escherichia coli sepsis. Am Rev Respir Dis 140: 974–980PubMedGoogle Scholar
  36. 36.
    Hoffmann P, Schockenhoff B (1985) Amrinon beim katecholaminrefraktären Herzversagen im septischen Schock. Anaesthesist 34: 663–559PubMedGoogle Scholar
  37. 37.
    Kalsner S (1969) Mechanism of hydrocortisone potentiation of responses to epinephrine and norepinephrine in rabbit aorta. Cir Res 24: 383–395Google Scholar
  38. 38.
    Kay HR, Afshari M, Barash P et al (1983) Measurement of ejection fraction by thermal dilution techniques. J Surg Res 34: 337–346PubMedCrossRefGoogle Scholar
  39. 39.
    Long WM, Sprung CL (1987) Corticosteroids, nonsteroidal anti-inflammatory drugs, and naloxone in the sepsis syndrome. World J Surg 11: 218–225PubMedCrossRefGoogle Scholar
  40. 40.
    Marks JD, Marks CB, Luce JM, Montgomery AB, Turner J, Metz CA, Murray JF (1990) Plasma tumor necrosis factor in patients with septic shock. Am Rev Respir Dis 141: 94–97PubMedGoogle Scholar
  41. 41.
    Meadows D, Edwards JD, Wilkins RG, Nightingale P (1988) Reversal of intractable septic shock with norepinephrine therapy. Crit Care Med 16: 663–666PubMedCrossRefGoogle Scholar
  42. 42.
    Messmer K (1987) Microcirculatory changes in endotoxinemia and septic shock. In: Vincent JL, Thijs LG (eds) Septic shock. Springer, Berlin Heidelberg New York Tokyo (Update in intensive care and emergency medicine, vol 4, pp 35–42 )Google Scholar
  43. 43.
    Natanson C, Danner RL, Elin RJ et al (1989) Role of endotoxemia in cardiovascular dysfunction and mortality. Escherichia coli and Staphylococcus aureus challenges in a canine model of human septic shock. J Clin Invest 83: 243–251PubMedCrossRefGoogle Scholar
  44. 44.
    Natanson C, Danner RL, Fink MP, MacVittie TJ, Walter RI, Conklin JJ, Parrillo JE (1988) Cardiovascular performance with E. coli challenges in a canine model of human sepsis. Am J Physiol 254: H558 - H569Google Scholar
  45. 45.
    Natanson C, Eichenholz PW, Danner RL et al (1989) Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J Exp Med 169: 823–832PubMedCrossRefGoogle Scholar
  46. 46.
    Ognibene FP, Rosenberg SA, Lotze M, Skibber J, Parker MM, Shelhamer JH, Parrillo JE (1988) Interleukin-2 administration causes reversible hemodynamic changes and left ventricular dysfunction similar to those seen in septic shock. Chest 94: 750–754PubMedCrossRefGoogle Scholar
  47. 47.
    Parker MM, McCarthy KE, Ognibene FP, Parrillo JE (1990) Right ventricular dysfunction and dilatation, similar to left ventricular changes, characterize the cardiac depression of septic shock in humans. Chest 97: 126–131PubMedCrossRefGoogle Scholar
  48. 48.
    Parker MM, Shelhammer JH, Bacharach SL et al (1984) Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 100: 483–490PubMedGoogle Scholar
  49. 49.
    Parrillo JE, Burch C, Shelhammer JH, Parker MM, Shuette W (1985) A circulating myocardial depressant substance in humans with septic shock. J Clin Invest 76: 1539–1553PubMedCrossRefGoogle Scholar
  50. 50.
    Parrillo JE, Parker MM, Natanson C, Suffredini AF, Danner RL, Cunnion RE, Ognibene FP (1990) Septic shock in humans: Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 113: 227–242PubMedGoogle Scholar
  51. 51.
    Prewitt RM (1990) Hemodynamic management in pulmonary embolism and acute hypoxemic respiratory failure. Crit Care Med 18: 561 - S69CrossRefGoogle Scholar
  52. 52.
    Prewitt RM, LDucas J (1987) Pathophysiology and treatment of right ventricular dysfunction due to pulmonary embolism. In: Vincent JL, Suter PM (eds) Cardipulmonary interactions in acute respiratory failure. Springer, Berlin Heidelberg New York Tokyo (Update in intensive care and emergency medicine, vol 2, pp 296–303 )Google Scholar
  53. 53.
    Prewitt RM, Ghignone M (1983) Treatment of right ventricular dysfunction in acute respiratory failure. Crit Care Med 11: 346–352PubMedCrossRefGoogle Scholar
  54. 54.
    Prough DS, Johnston WE (1989) Fluid resuscitation in septic shock: No solution yet. Anesth Analg 69: 699–704PubMedCrossRefGoogle Scholar
  55. 55.
    Radermacher P, Santak B, Wüst HJ, Tarnow J, Falke KJ (1990) Prostacyclin for the treatment of pulmonary hypertension in the adult respiratory distress syndrome: Effects on pulmonary capillary pressure and ventilation-perfusion distributions. Anesthesiology 72: 238–244PubMedCrossRefGoogle Scholar
  56. 56.
    Raper RF, Sibbald WJ (1988) The effects of coronary artery disease on cardiac function in nonhypotensive sepsis. Chest 94: 507–511PubMedCrossRefGoogle Scholar
  57. 57.
    Regnier B, Rapin M, Gory G, Lemaire F, Teisseire B, Harari A (1977) Haemodynamic effects of dopamine in septic shock. Intensive Care Med 3: 47–63PubMedCrossRefGoogle Scholar
  58. 58.
    Regnier B, Safran D, Carlet J, Teisseire B (1979) Comparative haemodynamic effects of dopamine and doputamine in septic shock. Intensive Care Med 5: 115–120PubMedCrossRefGoogle Scholar
  59. 59.
    Reinhart K (1989) Sauerstofftransport and Gewebeoxygenierung bei Sepsis and septischem Schock. In: Reinhart K, Eyrich K (Hrsg) Sepsis–Eine interdisziplinäre Herausforderung. Springer, Berlin Heidelberg New York Tokyo, S 137–152Google Scholar
  60. 60.
    Roberts DE, Dobson KE, Hall KW, Light RB (1988) Effects of prolonged naloxone infusion in septic shock. Lancet 11: 699–702CrossRefGoogle Scholar
  61. 61.
    Robertson RJ, Gilcher R, Metz KF et al. (1988) Effect of simulated altitude erythrocythemia in women on hemoglobin flow rate during exercise. J Appl Physiol 64: 1644–1649PubMedGoogle Scholar
  62. 62.
    Rock P, Silverman H, Plump D, Kecala Z, Smith P, Michael JR, Summer W (1985) Efficacy and safety of naloxone in septic shock. Crit Care Med 13: 28–33PubMedCrossRefGoogle Scholar
  63. 63.
    Royall JA, Berkow RL, Beckman JS, Cunningham MK, Matalon S, Freeman BA (1989) Tumor necrosis factor and interleukin la increase vascular endothelial permeability. Am J Physiol 257: L399 - L410PubMedGoogle Scholar
  64. 64.
    Schade OF (1990) Pentoxifylline increases survival in murine endotoxin shock and decreases formation of tumor necrosis factor. Circ Shock 31: 171–181PubMedGoogle Scholar
  65. 65.
    Schaer GL, Fink MP, Parrillo JE (1985) Norepinephrine alone vs. norepinephrine plus lowdose dopamin: Enhanced renal blood flow with combination pressor therapy. Crit Care Med 13: 492–496PubMedCrossRefGoogle Scholar
  66. 66.
    Schein RMH, Sprung CL, Marcial E, Napolitano L, Chernow B (1990) Plasma cortisol levels in patients with septic shock. Crit Care Med 18: 259–263PubMedCrossRefGoogle Scholar
  67. 67.
    Schirmer WJ, Schirmer JM, Fry DE (1989) Recombinant human tumor necrosis factor produces hemodynamic changes characteristic of sepsis and endotoxemia. Arch Surg 124: 445–448PubMedGoogle Scholar
  68. 68.
    Schremmer B, Dhainaut JF (1990) Heart failure in septic shock: Effects of inotropic support. Crit Care Med 18: S49 - S55PubMedCrossRefGoogle Scholar
  69. 69.
    Schreuder WO, Schneider AJ, Croeneveld ABJ, Thijs LG (1989) Effects of dopamine vs. norepinephrine on hemodynamics in septic shock. Emphasis on right ventricular performance. Chest 95: 1282–1288PubMedCrossRefGoogle Scholar
  70. 70.
    Schumacker PT, Cain SM (1987) The concept of critical oxygen delivery. Crit Care Med 13: 223–229Google Scholar
  71. 71.
    Sessler CN, Glauser FL, Davis D, Fowler AA (1988) Effects of platelet/activating factor antagonist SRI 63–441 on endotoxemia in sheep. J Appl Physiol 65: 2624–2631PubMedGoogle Scholar
  72. 72.
    Sheppard BC, Fraker DL, Norton JA (1989) Prevention and treatment of endotoxin and sepsis lethality with recombinant human tumor necrosis factor. Surgery 106: 156–162PubMedGoogle Scholar
  73. 73.
    Smith LW, McDonough KH (1988) Inotropic sensitivity to ß-adrenergic stimulation in early sepsis. Am J Physiol 255: H699 - H703PubMedGoogle Scholar
  74. 74.
    Sprung CL, Caralis PV, Marcial EH et al (1984) The effects of high-dose corticosteroids in patients with septic shock–A prospective, controlled study. N Engl J Med 311: 1137–1143PubMedCrossRefGoogle Scholar
  75. 75.
    Suffredini AF, Fromm RE, Parker MM, Brenner M, Kovacs JA, Wesley RA, Parrillo JE (1989) The cardiovascular response of normal humans to the administration of endotoxin. N Engl J Med 321: 280–287PubMedCrossRefGoogle Scholar
  76. 76.
    Vadas P, Pruzanski W, Stefanski E, Ruse J, Farewell V, McLaughlin J, Bombardier C (1988) Concordance of endogenous cortisol and phospholipase A2 levels in gram-negative septic shock: a prospective study. J Lab Clin Med 111: 584–590PubMedGoogle Scholar
  77. 77.
    Van Deventer SJH, Buller HR, ten Cate JW, Sturk A, Pauw W (1988) Endotoxinemia: an early predictor of septicemia in febrile patients. Lancet 1: 605–609PubMedCrossRefGoogle Scholar
  78. 78.
    Vincent J-L, Roman A, Kahn RJ (1990) Dobutamine administration in septic shock: Addition to a standard protocol. Crit Care Med 18: 689–693PubMedCrossRefGoogle Scholar
  79. 79.
    Vincent J-L, Linden P van der (1990) Septic shock: Particular type of acute circulatory failure. Crit Care Med 18: S70 - S74PubMedCrossRefGoogle Scholar
  80. 80.
    Yard AC, Kadowitz PJ (1972) Studies on the mechanism of hydrocortisone potentiation of vasoconstrictor responses to epinephrine in the anesthetized animal. Eur J Pharmacol 20: 1–9PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • H. Forst
  • T. Bein
  • J. Briegel
  • H. Hellinger
  • M. Haller
  • M. Stieglitz
  • F.-P. Lenhart

There are no affiliations available

Personalised recommendations